| Generic Drug/Consistency Evaluation Platform |
蟹爪兰
菊芋
榆树
郁金香
吊灯扶桑
Services and Solutions
Fukangren is committed to the research and development of new drugs and the consistency evaluation of generic drugs. It has a strong team of highly educated core personnel with rich experience in new drug R&D and industrialization.
CDMO
Focus on the development of high-end preparations and international cooperation in...
About Us
Beijing Fukangren Biopharmaceutical Technology Co., Ltd. started its drug R&D service in 1999 and is the CRO company with the longest continuous service time in China. Owns 3 pharmaceutical R&D centers, 1 clinical R&D center, 4 API production bases and 1 preparation production base
Contact Us
Sound organization, high-quality quality management team, complete document management system...
History
Committed to research and development of new drugs and consistency evaluation of generic drugs
Development Path
2021年
The Guiyang anti-tumor industry base was completed and put into use. A joint venture with Yangzhou Sanyao to establish a Jiangsu Furun API production base controlled by Fukangren
2020年
Complete A round of financing
Established Jinan Zhitong Clinical R&D Center
2018年
Joint venture with Shandong Ruiying to build an API production base
2017年
Established Jinan R&D Center
Established a joint venture with Shandong Fengjin Biopharmaceuticals to establish a raw material medicine industrial base in Yantai
2016年
Established Guiyang R&D Center
2014年
Paroxetine double-layer controlled-release tablet preparation technology transfer to EU
2011年
Acquired Foshan Yibaosheng Pharmaceutical Co., Ltd. and established a pilot plant for oral solids
2004年
Established a pilot base for APIs in Liaoyuan Yinying Pharmaceutical Co., Ltd.
2003年
The first batch to pass the “national high-tech enterprise” certification
The first batch to pass the “national high-tech enterprise” certification
1999年
Fukangren company was established
